Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: Results from the FRISC II trial

Heart

Volumn 89, Issue 3, 2003, Pages 287-292

  Janzon, Magnus ^a,b   Levin, L A ^b   Swahn, E ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0037369212     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.3.287     Document Type: Article

References (27)

1. FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
2. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRISC). Circulation 1997;96:61-8.
3. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. (Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group.) N Engl J Med 1997;337:447-52.
4. Fox KA. Implications of the organization to assess strategies for ischemic syndromes-2 (OASIS-2) study and the results in the context of other trials. Am J Cardiol 1999;84:26-31M.
5. Van Belle E, Lablanche JM, Bauters C, et al. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation 1998;97:26-33.
6. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-8.
7. Ernofsson M, Strekerud F, Toss H, et al. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998;79:491-4.
8. GUSTO Investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. (The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators.) N Engl J Med 1996;335:775-82.
9. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. (Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators.) N Engl J Med 1998;338:1498-505.
10. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. (Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators.) N Engl J Med 1998;338:1488-97.
11. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
12. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. (Fragmin in unstable coronary artery disease (FRISC) study group.) J Am Coll Cardiol 1997;29:43-8.
13. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. (Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events.) Circulation 1998;97:1702-7.
14. Dunn CJ, Jarvis B. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs 2000;60:203-37.
15. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary- artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-15.
16. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet 2000;356:9-16.
17. Granger CB. Strategies of patient care in acute coranary syndromes: ratianale for the global registry of acute caronary events (GRACE) registry. Am J Cardiol 2000;86:4-9M.
18. Fox KA, Cokkinos DV, Deckers J, et al. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J 2000;21:1440-9.
19. FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:701-7.
20. FASS 1997. Swedish drug catalogue, 1997.
21. The South County Council Cooperation Committee, Sweden, 1997.
22. Swedish Government. Statistical yearbook of Sweden 2001. Stockholm: Statistics Stockholm, 2001.
23. Financial Times. Currency converter. London: Financial Times, 2001.
24. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
25. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-200.
26. van Hout BA, Bowman L, Zelinger DJ, et al. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 far the prevention of ischemic complications. Eur Heart J 1998;19(suppl D):D59-66.
27. Janzon M, Levin L-A, Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease. Results from the FRISC II invasive trial. Eur Heart J 2002;23:31-40.